Principal Financial Group
GEVA

Principal Financial Group’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

Principal Financial Group’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-3,744
Closed -$365K – 2268
2015
Q1 		$365K Buy
3,744
+306
+9% +$32.4K ﹤0.01% 1879
2014
Q4 		$319K Sell
3,438
-1,124
-25% -$88.7K ﹤0.01% 1918
2014
Q3 		$314K Buy
4,562
+750
+20% +$53.7K ﹤0.01% 1912
2014
Q2 		$399K Sell
3,812
-1,488
-28% -$127K ﹤0.01% 1898
2014
Q1 		$440K Sell
5,300
-51
-1% -$4.72K ﹤0.01% 1891
2013
Q4 		$346K Buy
5,351
+612
+13% +$36.3K ﹤0.01% 1954
2013
Q3 		$300K Sell
4,739
-1,418
-23% -$69.8K ﹤0.01% 1962
2013
Q2 		$259K Buy
+6,157
New +$281K ﹤0.01% 1989

Principal Financial Group's GEVA Position: Q2 2015 in Review

Principal Financial Group sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 3,744 shares — an estimated $365K sold.

Principal Financial Group first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $440K in Q1 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • Principal Financial Group reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Principal Financial Group sold 3,744 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $365K.
  • Principal Financial Group first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • Principal Financial Group's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $440K in Q1 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on Principal Financial Group's 13F filing for Q2 2015, filed 10 Aug 2015.